90Y微球数量在肝动脉放射性栓塞术（TARE）中的剂量学重要性。 - Suppr | 超能文献

相似文献

1

The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE).90Y微球数量在肝动脉放射性栓塞术（TARE）中的剂量学重要性。

Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):634-8. doi: 10.1007/s00259-013-2674-6.

2

Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.钇-90 放射性栓塞治疗不可切除的混合型肝细胞-胆管细胞癌的结果。

J Vasc Interv Radiol. 2020 May;31(5):701-709. doi: 10.1016/j.jvir.2019.09.028. Epub 2020 Feb 29.

3

Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort.延长货架寿命（90）Y 玻璃微球的持续安全性和疗效：134 例患者队列的长期随访。

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):486-93. doi: 10.1007/s00259-013-2575-8. Epub 2013 Oct 10.

4

Histological changes in nontumoral liver secondary to radioembolization of hepatocellular carcinoma with yttrium 90-impregnated microspheres: report of two cases.肝细胞癌经钇90微球放射性栓塞后非肿瘤性肝脏的组织学变化：2例报告

Semin Liver Dis. 2014 Nov;34(4):465-8. doi: 10.1055/s-0034-1394145. Epub 2014 Nov 4.

5

Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models.经动脉放射栓塞治疗肝细胞癌和肝转移瘤：临床方面和剂量学模型。

Semin Radiat Oncol. 2020 Jan;30(1):68-76. doi: 10.1016/j.semradonc.2019.08.005.

6

Segmental Yttrium-90 Radioembolization Using Glass Microspheres Greater than 400 Gray for the Treatment of Intrahepatic Cholangiocarcinoma: A Preliminary Experience.采用大于 400 灰度的玻璃微球行节段性钇-90 放射性栓塞治疗肝内胆管细胞癌：初步经验。

J Vasc Interv Radiol. 2023 Nov;34(11):1970-1976.e1. doi: 10.1016/j.jvir.2023.07.028. Epub 2023 Aug 1.

7

Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.经动脉钇-90玻璃微球放射性栓塞治疗肝内胆管癌：单机构回顾性研究结果

J Vasc Interv Radiol. 2018 Aug;29(8):1101-1108. doi: 10.1016/j.jvir.2018.04.001. Epub 2018 Jul 2.

8

Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma.钇[90Y]微球放射性栓塞治疗不可切除的肝内胆管细胞癌。

Future Oncol. 2017 Jun;13(15):1301-1310. doi: 10.2217/fon-2017-0022. Epub 2017 Mar 27.

9

Segmental Pneumonitis after Radioembolization.

J Vasc Interv Radiol. 2018 Sep;29(9):1305-1306. doi: 10.1016/j.jvir.2018.04.010.

10

Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study.钇[90Y]经动脉放射性栓塞治疗化疗耐药性肝内胆管癌：一项前瞻性观察研究。

J Vasc Interv Radiol. 2019 Aug;30(8):1185-1192. doi: 10.1016/j.jvir.2019.03.018. Epub 2019 Jun 27.

引用本文的文献

1

Design and optimization of imageable microspheres for locoregional cancer therapy.用于局部区域癌症治疗的可成像微球的设计与优化。

Sci Rep. 2025 Jul 28;15(1):27487. doi: 10.1038/s41598-025-12182-5.

2

Tumor Dose as an Oncologic Predictor of Outcome in Patients with HCC Treated with Resin Y90 Microspheres.肿瘤剂量作为接受树脂钇90微球治疗的肝癌患者预后的肿瘤学预测指标。

Cardiovasc Intervent Radiol. 2025 Jul 10. doi: 10.1007/s00270-025-04113-8.

3

Radioembolization of hepatocellular carcinoma with Y glass microspheres: an earlier administration day unexpectedly improves tumour control probability.

本文引用的文献

1

The low hepatic toxicity per Gray of 90Y glass microspheres is linked to their transport in the arterial tree favoring a nonuniform trapping as observed in posttherapy PET imaging.90Y 玻璃微球每格雷的低肝毒性与其在动脉树中的运输有关，这有利于非均匀捕获，正如治疗后 PET 成像所观察到的那样。

J Nucl Med. 2014 Jan;55(1):135-40. doi: 10.2967/jnumed.113.126839. Epub 2013 Dec 2.

2

Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort.延长货架寿命（90）Y 玻璃微球的持续安全性和疗效：134 例患者队列的长期随访。

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):486-93. doi: 10.1007/s00259-013-2575-8. Epub 2013 Oct 10.

3